Project Details
Description
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.
| Status | Finished |
|---|---|
| Effective start/end date | 25/05/22 → 31/08/23 |
Collaborative partners
- National Vaccine and Serum Institute (NVSI) (lead)
- China National Biotec Group Company Limited
- Lanzhou Institute of Biological Products Co., Ltd.
- Beijing Institute of Biological Products Co., Ltd.
- Sheikh Khalifa Medical City
Keywords
- COVID-19
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
- Immunologic Factors
- Physiological Effects of Drugs
- Vaccines
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.